Thromboembolism in cancer patients: Pathogenesis and treatment

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 3, 2006, Pages 254-266

  Adess, Matthew ^b   Eisner, Robert ^b   Nand, Sucha ^b   Godwin, John ^b   Messmore Jr , Harry L ^a   Wehrmacher, William H ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Anticoagulants; Cancer; Cancer pro coagulants; Chemotherapy; Thromboembolism

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTITHROMBIN III; AROMATASE INHIBITOR; ASPARAGINASE; BLEOMYCIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DIETHYLSTILBESTROL; DOCETAXEL; DOXORUBICIN; ERYTHROPOIETIN; ESTRAMUSTINE; ESTROGEN; FLUOROURACIL; GEMTUZUMAB OZOGAMICIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; MITOXANTRONE; PREDNISONE; TAMOXIFEN; THALIDOMIDE; TIOGUANINE; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG; VINBLASTINE; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANGINA PECTORIS; BLEEDING; BREAST CANCER; BUDD CHIARI SYNDROME; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER STAGING; CANCER THERAPY; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CEREBRAL SINUS THROMBOSIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DIAGNOSTIC IMAGING; DRUG EFFICACY; HEART INFARCTION; HEMOLYTIC UREMIC SYNDROME; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; LIVER VEIN THROMBOSIS; LIVER VENOOCCLUSIVE DISEASE; LUNG EMBOLISM; METASTASIS; MYELOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT CARE; PHLEBITIS; PHLEBOGRAPHY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTECTIVE CLOTHING; REVIEW; RISK; RISK FACTOR; STROKE; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; FIBRINOLYTIC AGENTS; HUMANS; NEOPLASMS; PREMEDICATION; RISK FACTORS; THROMBOEMBOLISM;

EID: 33748752692     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606291432     Document Type: Review

References (90)

1. Blom JW, Doggen CJM, Osanto S, et al. Malignancies, prothrombotic mutations and the risk of venous thrombosis. JAMA 2005;293:715.
2. Thodiyil PA, Walsh DC, Kakka AK. Thromboprophylaxis in the cancer patient. Acta Haematol 2001;106:73.
3. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l' Hotel Dieu de Paris.London. The New Sydenham Society 1865;3:94.
4. Rance A, Emmerick J, Guedj C, et al. Occult cancer in patients with bilateral deep vein thrombosis. Lancet 1997;350:1448.
5. Bura A, Caillerux N, Bienvenu B, et al. Incidence and prognosis of cancer associated with bilateral venous thrombosis: A prospective study of 103 patients. J Thromb Haemost 2004;2:441.
6. Virchow R. Cellular Pathology. London: Churchill, 1866.
7. Nand S, Fisher S, Salgia R, et al. Hemostatic abnormalities in untreated cancer: Incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol 1987;5:1998.
8. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586.
9. Messmore H, Wehrmacher W. Disseminated intravascular coagulation. e Postgrad Med 2002;March 1.
10. De Cicco M. The prothrombotic state in cancer: Pathogenic mechanisms. Crit Rev Oncol Hematol 2004;50:187.
11. Lee A. Cancer and thromboembolic disease: Pathogenic mechanisms. Cancer Treat Rev 2002;28:137.
12. Rickles F, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001;102:V215.
13. Sampson M, Kakkar A. Coagulation proteases and human cancer. Biochem Soc Trans 2002;30:201.
14. Rickles F, Patierno S, Fernandez P. Tissue factor, thrombin, and cancer. Chest 2003;124:58S.
15. Yu J, May L, Klement P, et al. Oncogenes as regulators of tissue factor expression in cancer: Implications for tumor angiogenesis and anti-cancer therapy. Semin Thromb Hemost 2004;30:21.
16. Yu J, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis. Blood 2005;105:1734.
17. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: A cysteine proteinase from malignant tissue. Biochemistry 1985;24:5558.
18. Falanga A, Alession MG, Donati MB, et al. A new procoagulant in acute leukemia. Blood 1988;71:870.
19. Gordon SG, Benson B. Analysis of serum cancer procoagulant activity its possible use as a tumor marker. Thromb Res 1989;56:431.
20. Donati MB, Flanga A, Consonni R, et al. Cancer procoagulant in acute nonlymphoid leukemia: Relationship of enzyme detection to disease activity. Thromb Haemost 1990;64:11.
21. Kazama Y, Hamamoto T, Foster D, et al. Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation. J Biol Chem 1995;270:66.
22. Moore KI, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989;73:159.
23. Yuan A, Chen JJ, Yao PL, et al. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 2005;10:853.
24. van Aken BE, Reitsma PH, Rosendaal FR. Interleukin-8 and venous thrombosis: Evidence for a role of inflammation in thrombosis. Br J Haematol 2002;116:173.
25. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436.
26. Wojtukiewicz M, Sierko E, Zacharksi L, et al. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Semin Thromb Hemost 2003;29:291.
27. Kwaan HC, Keet HN. Fibrinolysis and cancer. Semin Thromb Haemostasis 1990;16:230.
28. Kwaan HC, Keet HN. Fibrinolysis and cancer. Semin Thromb Hemost 1990;16:230.
29. Wahrenbrock M, Borsig L, Le D, et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 2003;112:853.
30. Bauer KA, Ten Cate H, Barzegar S, et al. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989;74:165.
31. Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer. Immunohistochemical localization in situ of clotting proteins and VEGF in human cancers. Am J Pathol 1998;152:399.
32. Bastida E, Ordinas A. Platelet contribution to the formation of metastatic foci: The role of cancer cell-induced platelet activation. Haemostasis 1988;18:29.
33. Lee A, Levine M. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999;25:137.
34. Zierler BK. Ultrasonography and diagnosis of venous thromboembolism. Circulation 2004;109:I9.
35. Stevens SM, Elliott CG, Chan KJ, et al. Withholding anticoagulation after a negative result on duplex ultrasonography for suspected symptomatic deep venous thrombosis. Ann Intern Med 2004;140:985.
36. Fraser DG, Moody AR, Morgan PS, et al. Iliac compression syndrome and recanalism of femoropopliteal and iliac venous thrombosis: A prospective study with magnetic resonance venography. J Vasc Surg 2004;40:612.
37. Prandoni P, Piccioli A. Venous thromboembolism and cancer: A two-way clinical association. Front Biosci 1997;2:e12.
38. Clahsen PC, van de Velde CJ, Julien JP, et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: An EORTC Breast Cancer Cooperative Group Study. J Clin Oncol 1994;12:1266.
39. Weiss RB, Tormey DC, Holland JF, et al. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep. 1981;65:677.
40. Rogers JS, Murgo AJ, Fontana JA, et al. Chemotherapy for breast cancer decreases plasma proteins C and S. J Clin Oncol 1988;6:276.
41. von Tempelhoff GF, Dietrich M, Hommel G, Heilman L. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 1996;14:2560.
42. Elliot MA, Wolf RC, Hook CC, et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase containing multi agent regimens: Incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma 2004;45:1545.
43. Mitchell L, Andrea M, et al. Trend to efficacy and safety using at concentrate in prevention of thrombosis in children receiving 1 asparaginase for ALL. Results of the PAARKA study. Thromb Haemost 2003;90:235.
44. Pui CH, Jackson CW, Chesney CM, et al. Involvement of von Willebrand factor in thrombosis following asparaginase-prednisone-vincristine therapy for acute leukemia. Am J Hematol 1987;25:291.
45. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286.
46. Rutqvist LE, Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. J Nat Cancer Inst 1993;85:1398.
47. Dowsett M. Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer. Semin Oncol 2003;30:58.
48. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer with tamoxifen: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst Monogr. 1998;90:1371.
49. Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003;21:3588.
50. McCaskill-Stevens W, Wilson W, Bryant J, et al. Contralateral breast cancer and thromboembolic events in African-American women treated with tamoxifen. J Natl Cancer Inst 2004;96:1762.
51. Geiger AM, Fischberg GM, Chen W, Bernstein L. Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004;96:1528.
52. Bushnell CD, Bernstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: A meta-analysis. Neurology 2004;63:1230.
53. Levine M, Hirsh J, Gent M, et al. Double blind randomized trial of very low dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886.
54. Savarese DM. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001;19:2509.
55. Petrylak D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513.
56. Sinibaldi VJ. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen-independent prostate carcinoma. Cancer 2002;94:1457.
57. Medina P, Sipols JM, George JN, et al. Drug-associated thombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001;8:286.
58. Sheldon R. A syndrome of microangiopathic hemolytic anemia, renal impairment and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 1986;58:1428.
59. Lesesne JB. Cancer-associated hemolytic uremic syndrome: Analysis of 85 cases from a national registry. J Clin Oncol 1989;7:781.
60. Cantrell JE, Phillips TM, Schein PS, et al. Carcinoma-associated hemolytic uremic syndrome: A complication of mitomycin C chemotherapy. J Clin Oncol 1985;3:723.
61. Charba D, Moake JL, Harris MA, et al. Abnormalities of von Willebrand factor multimers in drug-associated thrombotic microangiopathies. Am J Hematol 1993;42:268.
62. Monteagudo J, Pereira A, Roig S, et al. Investigation of plasma von Willebrand factor and circulating platelet activity in mitomycin C-related hemolytic uremic syndrome. Am J Hematol 1990;33:46.
63. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide. Identification of prognostic factors in a Phase 2 study. Blood 2001;98:492.
64. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614.
65. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implication for therapy. Blood 2002;100:1168.
66. Ward CM, Weber D, Ginsberg C, et al. Elevated levels of factor VIII and vWF after thalidomide treatment for malignancy: Relationship to thromboembolic events (abstract). Hematol J 2003;4(Suppl 1).
67. Weber D, et al. Correlation of thrombotic/embolic events with feature of hypercoagulability in previously untreated patients before and after treatment with thalidomide or thalidomide/dexamethasone. ASH 2002; (abstract 787) 100.
68. Auwerda HJA. Progressive multiple myeloma is associated with increased serum VEGF. ASH 2002; (abstract 5059) 100.
69. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60.
70. Wadleigh M, Richardson P, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003;102:1578.
71. Cohen AD, Luger SM, Sickles C, et al. Gemtuzamab ozogamicin monotherapy for relapsed AML after hematopoietic stem cell transplant: Efficacy and incidence of hepatic veno occlusive disease. Bone Marrow Transplant 2002;30:23.
72. Ibrahim RB, Peres E, Dansey R, et al. Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity. Ann Pharmacother 2004;38:1053.
73. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb 1991;10:1.
74. Nand S, Wong W, Yuen B, et al. Heparin-induced thrombocytopenia with thrombosis. Analysis of risk factors and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997;56:12.
75. Warkentin T, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330.
76. Samtleben W, Ehmer B, Lutz-Knochenhauer I, et al. Side effects during recombinant erythropoietin therapy in 2000 ESRD patients. Contrib Nephrol 1991;88:107.
77. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071.
78. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081.
79. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092.
80. Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004;9:207.
81. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S.
82. Lee AYY, Levine MN. Venous thromboembolism and cancer: Risks and outcomes. Circulation 2003;107:I17.
83. Deitcher SR. Cancer-related deep venous thrombosis: Clinical importance, treatment challenges, and management strategies. Semin Thromb Hemost 2003;29:247.
84. Lee AYY, Levine MN, Ross I, et al. Low-molecular-weight heparin versus coumadin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146.
85. Bick R. Cancer-associated thrombosis: New advances in therapy (invited editorial). N Engl J Med 2003;349:109.
86. Frenkel E, Bick R. Thrombohemorrhagic Defects Associated with Malignancy. In: Disorders of Thrombosis and Hemostasis. Philadelphia: Lippincott Williams & Wilkins, 2002;265.
87. Bick R. Dalterparin versus current standard therapy in the treatment of cancer-associated thrombosis: An evidence-based analysis - is warfarin still warranted? J Support Oncol 2006 (in press).
88. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia. Arch Intern Med. 2004;164:361.
89. Weitz J, Hirsh J, Samama MM. New anticoagulant drugs. Chest 2004;126(Suppl 3):265S.
90. Houston DS. Tissue factor - a therapeutic target for thrombotic disorders. Expert Opin Ther Targets. 2002;6:159.